Cagrilintide and the Amylin Pathway: The Other Weight Loss Mechanism

What Is Amylin?

Amylin (also known as islet amyloid polypeptide, or IAPP) is probably the most important metabolic hormone you've never heard of. It's a 37-amino-acid peptide produced by the same pancreatic beta cells that make insulin, and it's co-secreted with insulin after meals in a roughly 1:100 ratio (amylin:insulin).

It was discovered relatively recently (1987) and its clinical significance wasn't fully appreciated until the 2000s. Pramlintide (brand name Symlin), a synthetic amylin analog, was approved for diabetes in 2005, but it never achieved blockbuster status because it required multiple daily injections and the weight loss effects, while real, were modest.

Cagrilintide is the next attempt — a long-acting amylin analog designed for the once-weekly convenience that made semaglutide successful.

How the Pathway Works

Amylin acts through calcitonin receptors (CTR) and receptor activity-modifying proteins (RAMPs) in the brain, particularly in the area postrema and nucleus tractus solitarius — brainstem regions that process satiety signals.

Three main effects:

Gastric emptying: Amylin slows the rate at which food leaves the stomach, similar to GLP-1. But the pathway is different: amylin acts primarily through the vagus nerve and brainstem, while GLP-1 works through direct receptor activation in the stomach and enteric nervous system. Two different brakes on the same process.

Glucagon suppression: Amylin inhibits post-meal glucagon secretion from pancreatic alpha cells. This prevents the liver from dumping glucose into the bloodstream when it's not needed — a common problem in type 2 diabetes.

Central satiety: Amylin activates neurons in the area postrema that project to the hypothalamus, reducing appetite. Importantly, the neuronal populations involved are different from those activated by GLP-1. This is the key insight behind combination therapy: two hormones hitting different populations of satiety neurons should produce a stronger effect than doubling the dose of either one alone.

Cagrilintide

Native amylin has a half-life of about 13 minutes — way too short for practical use. Pramlintide improved this but still required 2-3 daily injections. Cagrilintide solves the duration problem.

Novo Nordisk modified the amylin sequence and attached a C-18 fatty acid chain (the same albumin-binding strategy used in semaglutide). The result: a once-weekly injectable amylin analog with a half-life of approximately 7 days.

As a standalone drug, cagrilintide produced about 10-11% body weight loss in Phase 2 trials — respectable, but not as impressive as semaglutide (15-17%) or tirzepatide (22%). The real potential of cagrilintide isn't solo use — it's what happens when you combine it with semaglutide.

CagriSema: The Combination

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg + semaglutide 2.4 mg in a single once-weekly injection. The Phase 3 REDEFINE trials have been the most anticipated obesity trial results since tirzepatide.

The results: up to 25.3% body weight loss at 68 weeks in the REDEFINE 1 trial. This is approximately 8 percentage points more than semaglutide alone and puts CagriSema in the same ballpark as tirzepatide, with a completely different pharmacological approach.

Why does the combination work so well? Think of it this way: semaglutide reduces appetite through GLP-1 receptor-expressing neurons. Cagrilintide reduces appetite through amylin receptor-expressing neurons. These are different populations of cells in different brain regions. You're hitting the "I'm not hungry" circuit from two independent directions. The result is more than additive.

The nausea profile is also interesting. While you might expect stacking two appetite-suppressing drugs to worsen GI side effects, the Phase 3 data showed nausea rates comparable to semaglutide alone. The hypothesis is that amylin-mediated satiety doesn't rely as heavily on delayed gastric emptying as GLP-1, so the nausea driver isn't doubled.

Amylin vs GLP-1

The Future

CagriSema is expected to receive FDA approval and will likely become a first-line option for obesity treatment. But the broader implication is that the future of obesity pharmacotherapy is probably multi-mechanism, not single-target.

If semaglutide proved that GLP-1 agonism works, and tirzepatide proved that dual GIP/GLP-1 agonism works better, and CagriSema proves that amylin + GLP-1 works better still — the next logical step is combinations of all three, or even four or five mechanisms combined. Retatrutide (triple agonist) with cagrilintide? That's four receptor systems in one regimen.

For researchers, cagrilintide and the amylin pathway represent an important piece of the obesity puzzle that's been overshadowed by the GLP-1 spotlight. Understanding this pathway will be increasingly relevant as combination therapies become the standard of care.